Innovent's DOVBLERON Receives Second NDA Approval for Lung Cancer Treatment in China Innovent Biologics has achieved a milestone as its drug DOVBLERON gains NDA approval for treating advanced lung cancer in China, enhancing treatment options.

Innovent's DOVBLERON Receives Second NDA Approval for Lung Cancer Treatment in China #China #Suzhou #Lung_Cancer #DOVBLERON #Innovent

Innovent's DOVBLERON® Approved in China for Advanced Lung Cancer Treatment Innovent Biologics has received approval for DOVBLERON®, a next-gen ROS1 inhibitor, in China to treat advanced lung cancer. This marks a significant advancement in precision oncology.

Innovent's DOVBLERON® Approved in China for Advanced Lung Cancer Treatment #China #Suzhou #DOVBLERON #Innovent #ROS1_Inhibitor